Christos Mantzoros MD DSc PhD h.c. mult.’s Post

Much needed and up to date review by the Mantzoros group at Harvard Medical School of all anti obesity medications in phase II-III clinical trials. Very useful in understanding the competitive landscape, the promising future solutions for a major public health problem and importantly what makes certain compounds fail to advance. A field of major medical and market importance. Our recently published systematic review summarizing all phase 2 & 3 anti-obesity medications is #OpenAccess ! Link to the full-text publication: https://lnkd.in/dMz5B9QF Accompanied by an editorial: https://lnkd.in/dU9mJXmW #Obesity #Management #ClinicalTrials #Drugs #SystematicReview

  • graphical user interface, text, application, email
Vladimir Vexler

Accomplished Biopharmaceutical R&D Scientist, Drug Developer and Executive

4mo

Interesting and helpful

Like
Reply

Awesome!

Like
Reply
James Smith

Lecturer (Assistant Professor) University of Leeds, UK

4mo

Very Helpful

Like
Reply
Lila Amirali

Chair, Canadian Academy of Child and Adolescent Psychiatry (CACAP – ACPEA), Associate Professor at Université de Montréal

3mo

Congratulations Christos Mantzoros MD DSc PhD h.c. mult. Great work!

Like
Reply
Toni Vidal-Puig MD PhD FRCP FMedSci MBA

Professor of Molecular Nutrition and Metabolism at the University of Cambridge. Research Scientist at Cambridge University Nanjing Centre of Technology and Innovation (CUNJC), Nanjing.

4mo

Congrats

Like
Reply
GEORGIA LI, M.D.

Medical Executive Accomplished In Advancing Clinical Development of SMDs, MABs, SiRNA, CGT to Registration Across Major & Rare Indicators in Organ Fibrosis (NASH, PBC, PSC, IPF, DKD), Neurodegenerative Dz, & IO Oncology

3mo

Christos Mantzoros MD DSc PhD h.c. mult. Very insightful, Christos!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics